Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta

University of Washington Seattle, Seattle, Washington, United States
Nature Genetics (Impact Factor: 29.65). 04/2007; 39(3):359-65. DOI: 10.1038/ng1968
Source: PubMed

ABSTRACT A recessive form of severe osteogenesis imperfecta that is not caused by mutations in type I collagen has long been suspected. Mutations in human CRTAP (cartilage-associated protein) causing recessive bone disease have been reported. CRTAP forms a complex with cyclophilin B and prolyl 3-hydroxylase 1, which is encoded by LEPRE1 and hydroxylates one residue in type I collagen, alpha1(I)Pro986. We present the first five cases of a new recessive bone disorder resulting from null LEPRE1 alleles; its phenotype overlaps with lethal/severe osteogenesis imperfecta but has distinctive features. Furthermore, a mutant allele from West Africa, also found in African Americans, occurs in four of five cases. All proband LEPRE1 mutations led to premature termination codons and minimal mRNA and protein. Proband collagen had minimal 3-hydroxylation of alpha1(I)Pro986 but excess lysyl hydroxylation and glycosylation along the collagen helix. Proband collagen secretion was moderately delayed, but total collagen secretion was increased. Prolyl 3-hydroxylase 1 is therefore crucial for bone development and collagen helix formation.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Bone is a composite material that resembles reinforced concrete. The collagen matrix plays the role of reinforcement, whereas hydroxyapatite crystals are cementing material. Collagen fibers are responsible for the tensile strength of bones and prevent fractures from extending; the mineral phase is able to withstand compaction loads. A right balance of these two parts synergistically provides the required stiffness for bone. Collagen abnormalities, such as reduced amount, disturbed composition, defects in structure and/or supramolecular organization as well as insufficient or defective mineralization, lead to osteogenesis imperfecta (OI), also known as brittle bone disease. Until recently, mutations in the type I collagen genes COL1A1 and COL1A2 were the only known causes of the disease, which cover about 90 % of diagnosed OI. Within the last decade, we have witnessed a burst in the identification of new OI mutations in other genes. Here we summarize our knowledge of these mutations and their impact on bone quality.
    12/2013; 1(4):239-246. DOI:10.1007/s40142-013-0026-2
  • [Show abstract] [Hide abstract]
    ABSTRACT: The present study evaluates a fetal skeleton (B532) from the Romano-Byzantine period Kellis 2 cemetery (circa A.D. 50–A.D. 450), in the Dakhleh Oasis, Egypt. This skeleton displays abnormal skeletal characteristics consisting of severe bowing of the long bones. Differential diagnoses using macroscopic and radiographic analyses indicate that this individual's pathological condition was caused by osteogenesis imperfecta (IO), possibly Type IIB/III, or Type IV OI, corroborating with characteristics reported in the clinical literature. Due to the severe bowing of the long bones, traditional aging methods could not be used for this individual. Baysian estimates of age indicate this individual was a fetus of approximately 38 weeks gestation. Although this condition has been diagnosed previously in the archeological literature, this burial represents the youngest aged example of osteogenesis imperfecta reported to date.
    12/2011; 1(3-4):188-199. DOI:10.1016/j.ijpp.2012.02.001
  • [Show abstract] [Hide abstract]
    ABSTRACT: Osteogenesis imperfecta (OI) is a rare inherited skeletal disease, characterized by bone fragility and low bone density. The mutations in this disorder have been widely reported to be on various exonal hotspots of the candidate genes, including COL1A1, COL1A2, CRTAP, LEPRE1, and FKBP10, thus creating a great demand for precise genetic tests. However, large genome sizes make the process daunting and the analyses, inefficient and expensive. Therefore, we aimed at developing a fast, accurate, efficient, and cheaper sequencing platform for OI diagnosis; and to this end, use of an advanced array-based technique was proposed. A CustomSeq Affymetrix Resequencing Array was established for high-throughput sequencing of five genes simultaneously. Genomic DNA extraction from 13 OI patients and 85 normal controls and amplification using long-range PCR (LR-PCR) were followed by DNA fragmentation and chip hybridization, according to standard Affymetrix protocols. Hybridization signals were determined using GeneChip Sequence Analysis Software (GSEQ). To examine the feasibility, the outcome from new resequencing approach was validated by conventional capillary sequencing method. Overall call rates using resequencing array was 96-98% and the agreement between microarray and capillary sequencing was 99.99%. 11 out of 13 OI patients with pathogenic mutations were successfully detected by the chip analysis without adjustment, and one mutation could also be identified using manual visual inspection. A high-throughput resequencing array was developed that detects the disease-associated mutations in OI, providing a potential tool to facilitate large-scale genetic screening for OI patients. Through this method, a novel mutation was also found.
    PLoS ONE 03/2015; 10(3):e0119553. DOI:10.1371/journal.pone.0119553 · 3.53 Impact Factor

Full-text (2 Sources)

Available from
Jun 3, 2014